We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here




Amsterdam. March 5th 2019. Norgine B.V. today announced that it has expanded its partnership with Noventure S.L. by entering into an exclusive distribution agreement for GELSECTAN® in France. This deal expands on Norgine’s existing collaboration with Noventure S.L. under which Norgine distributes GELSECTAN® in Portugal, Spain, Andorra and the Italian Republic (incl. Vatican City and San Marino). GELSECTAN ® is a Class IIa CE marked medical device used as a treatment for irritable bowel syndrome (IBS) with diarrhoea (IBS-D). IBS is a chronic bowel problem, characterized by abdominal pain, bloating, and changes in bowel habit. 1 Diarrhoea is one of the symptoms often associated with irritable bowel syndrome. GELSECTAN® is available in capsules for oral use.

Read more

GELSECTAN® launched in Finland

We are glad to announce the launch of GELSECTAN® in Finland by our partner company Sabora. GELSECTAN® belongs to a new class of products defined as “mucosal protectors”, which help restore the normal function of the epithelial barrier in the gut. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhea, pain and bloating.

Read more

Xilaplus® launched in France by Therabel

Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée. XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes and associated symptoms in adults, children, and infants.

Read more

Let's meet in..

2020, Mar 20

EAU 20

Read more

2020, May 13

EWMA 2020

Read more

2020, Jun 03

ESPGHAN 6th World Congress

Read more